http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4442106-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fb3689bb224dbbee5f993de522c694e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 |
| filingDate | 1981-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1984-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba3ed66602525f8b773e399250d620a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f81c30a5285d95bcaf16a23168ea356e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36de48a48b399448e51d60e11fa50616 |
| publicationDate | 1984-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-4442106-A |
| titleOfInvention | Quinoline derivatives, pharmaceutical compositions containing such compounds, and methods of treating cardiovascular conditions with them |
| abstract | The invention is concerned with novel quinoline derivatives having cardiovascular activities of formula 1 ##STR1## in which A--B is --CH 2 --CH 2 --, --CHOH--CH 2 , --CH 2 --CHOH--, --C(O)--CH 2 --, --CH 2 --C(O)--, --C(NOR 5 )--CH 2 -- or --CH 2 --C(NOR 5 )--; R 1 is hydrogen, hydroxy or lower alkoxy; R 2 is lower alkyl, hydroxy, lower alkoxy or CF 3 ; R 3 is ethyl or vinyl; R 4 is C 1-9 alkyl, C 2-9 hydroxyalkyl or lower alkoxyalkyl, C 5-6 cycloalkyl, C 3-6 cycloalkyl lower alkyl, cyano lower alkyl, lower alkenyl, lower alkynyl, tetrahydrofurfuryl, mono- or di-lower alkylamino lower alkyl; mono- or di-lower alkylamino lower hydroxyalkyl; phenyl C 1-4 alkyl, phenyl C 1-4 hydroxy-alkyl, diphenyl C 1-4 alkyl, benzoyl C 1-4 alkyl, furyl C 1-4 alkyl, thienyl C 1-4 alkyl, furoyl C 1-4 alkyl or thienoyl C 1-4 alkyl, which groups may be optionally substituted in the aromatic nucleus, and R 5 is lower alkyl, whereby the substituents at the 3- and 4-positions of the piperidine ring are in the cis-position. The compounds of the formula may be in the form of their optically active enantiomers and/or their therapeutically acceptable salts. Furthermore the invention provides pharmaceutical compositions possessing cardiovascular activities, in which as active compound at least a compound of the above formula is used. Methods for the preparation of the pharmaceutical compositions and of the active compounds are also disclosed and covered by the invention. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011060036-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4613607-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006223853-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4921862-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4792561-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004132722-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7304053-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002099215-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7476680-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7135483-B2 |
| priorityDate | 1980-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 279.